Эффективность и безопасность раствора тобрамицина для ингаляций в лечении синегнойной инфекции при муковисцидозе

муковисцидоз, Pseudomonas aeruginosa, тобрамицин, ингаляции, фармакокинетика, эффективность, безопасность

1. Cystic fibrosis foundation: About cystic fibrosis. www.cff.org

2. Cystic Fibrosis Fact Sheet 2006. www.lungusa.org

3. American Lung Association (ALA). Lung Disease Data: 2008. Available at: www.lungusa.org. Accessed on June 2008.

4. http://www.cf-rf.ru/content/ru/about_mucoviscidosis.html доступно: 03.2010.

5. Davies J.C., Alton E.W., Bush A. Cystic fibrosis. Brit. Med. J. 2007; 335: 1255-1259.

6. Flume P.A., S'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines. Chronic medication for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957-969.

7. Dopfer R., Brand P., Mullinger B. et al. Inhalation of tobramycin in patient with cystic fibrosis: comparison of two methods. J. Physiol. Pharmacol. 2007; 58 (suppl. 5): 141-154.

8. Maselli J.H., Sontag M.K., Norris J.M. et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr. Pulmonol. 2003; 35: 257-262

9. Gibson R.L., Emerson J., McNamara S. et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 841-849.

10. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии: 3-е изд.; 2008.

11. Moriarti T.F. et al. Intrapulmonary concentrations of tobramycin and ceftazidime archived after intravenous administration for the treatment of cistic fibrosis lung infections. J. Cyst. Fibros. 2006: 5 (suppl. 1); S20.

12. Гуревич К.Г., Белоусов Ю.Б. Клиническая фармакокинетика. М.: Литтерра; 2005.

13. Bowman C.M. The longterm use of inhaled tobramycin in patients with cystic fibrosis. J. Cystic Fibrosis. 2002; 1: s194-s198

14. Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.

15. Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and P. aeruginosa infection. Pediatric. Pulmonol. 2002; 33: 269-276.

16. Ламберт П.А., Конвей Б.Р. Сравнение фармацевтического качества генерических препаратов цефтриаксона и роцефина. Клин. микробиол. антимикроб. химиотер. 2004; 6 (3): 260-272.

17. Wetterich U., Mutschler E., Rangoonwala R. Comparative quality assurance investigations of claforan and cefotaxime generics from India in respect to particulate matter. Proceedings of the 20th International Congress on Chemotherapy. Sydney, Australia, June 29July 3. 1997.

18. Lehr H.A., Brunner J., Rangoonwala R., Kirkpatrick C.J. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in post ischemic striated muscle. Am. J. Respir. Crit. Care Med. 2002; 165: 514-520.

19. Nightingale C.H. A survey of the quality of generic clarithromycin product from 13 countries. Clin. Drug Invest. 2000; 19: 293-305.